High-risk PCa: adding docetaxel to ADT+RT boosts survival

  • Rosenthal SA & al.
  • J Clin Oncol
  • 12 Mar 2019

  • curated by Deepa Koli
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Adding docetaxel-based chemotherapy to standard androgen-deprivation therapy and radiotherapy (ADT+RT) improves OS in high-risk nonmetastatic prostate cancer (PCa).
  • Data also show improved disease-free survival (DFS) and reduction in the rate of distant metastasis.

Why this matters

  • Findings represent a new option for select men with high-risk localized PCa.

Study design

  • Phase 3, randomized NRG Oncology RTOG 0521 study of 563 patients with high-risk nonmetastatic PCa, randomly assigned to standard long-term ADT+RT with or without adjuvant docetaxel+prednisone.
  • Funding: National Cancer Institute; Sanofi.

Key results

  • Median follow-up, 5.7 years.
  • Patients in the ADT+RT+docetaxel group showed significant improvement in the:
    • 4-year OS rate (93.3% vs 88.7%; HR, 0.69; P=.034).
    • 6-year distant metastasis rate (9.1% vs 14.0%; HR, 0.60; P=.044).
    • 6-year DFS rate (65.4% vs 54.9%; HR, 0.76; P=.043).
  • 5-year PSA failure-free rates were similar between groups (P=.19).
  • Hematologic toxicities were higher in the ADT+RT+docetaxel group.
  • Treatment was well tolerated in both groups.

Limitations

  • Open-label design.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit